OcuTerra OTT166-201
A short video from the Dr. David Tanzer, Chief Medical Officer of OcuTerra summarizing the OTT166 Eye drops trial.
Most Recent Videos
0:57Ubavka DeNoble, Senior Medical Officer for Parexel Biotech, shares the story of how her best friend’s devastating disease and her first job in the drug industry overlapped. Both experiences taught her
3:04Aleksandar shares about his work as a Senior Clinical Operations Leader (COL) at Parexel Serbia. He is energized by the fact that each task contributes to bringing new and innovative therapies to the
2:38Rory talks about his seven-year career path at Parexel in the United States, growing from a Clinical Operations Leader (COL) into a Senior position. He enjoys the flexibility of working remotely, wher
1:27Stephanie Gonzalez, Vice President and Head of Biotech Operations for EMEA, compares her preparation for competing in Ironman Triathlon with planning for clinical trials, and the importance of ensurin
2:09Anthony shares how Parexel's flexibility allows him to keep some clinical responsibilities. By receiving more control over his schedule compared to working purely as a clinician, he improved his work-
2:38Rory talks about his seven-year career path at Parexel in the United States, growing from a Clinical Operations Leader (COL) into a Senior position. He enjoys the flexibility of working remotely, wher
3:04Aleksandar shares about his work as a Senior Clinical Operations Leader (COL) at Parexel Serbia. He is energized by the fact that each task contributes to bringing new and innovative therapies to the
13:18ICH Q9 (1) focuses on Quality Risk Management. Revisions may influence how we apply and perform risk management in clinical trials. In part three of our RBQM video series, Amy Kissam-Sands, Senior Vic
9:59While patient safety remains the primary concern of guidance ICH E6, revision 3 further directs sponsors to include patients in the research process. In part two of our RBQM video series, Amy Kissam-S
10:17RBQM calls for new ways of operating that will change the clinical development process. ICH E8 (R1) will guide revisions and alignments for the suite of ICH efficacy guidelines. Parexel’s RBQM experts
